STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 108 filers reported holding STOKE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $46,949 | -90.7% | 11,916 | -74.8% | 0.00% | – |
| Q2 2023 | $502,491 | +33.6% | 47,271 | +4.7% | 0.00% | – |
| Q1 2023 | $376,116 | -8.3% | 45,152 | 0.0% | 0.00% | – |
| Q4 2022 | $409,997 | -30.1% | 45,152 | -0.1% | 0.00% | – |
| Q3 2022 | $586,576 | -2.6% | 45,185 | -0.8% | 0.00% | – |
| Q2 2022 | $602,505 | -20.2% | 45,529 | +32.0% | 0.00% | – |
| Q1 2022 | $755,349 | +188.3% | 34,499 | +216.5% | 0.00% | – |
| Q4 2021 | $262,000 | -3.7% | 10,901 | +2.0% | 0.00% | – |
| Q3 2021 | $272,000 | -29.4% | 10,683 | -6.6% | 0.00% | – |
| Q2 2021 | $385,000 | +21.1% | 11,440 | +39.6% | 0.00% | – |
| Q1 2021 | $318,000 | -35.0% | 8,196 | +3.8% | 0.00% | – |
| Q4 2020 | $489,000 | +91.8% | 7,896 | +3.6% | 0.00% | – |
| Q3 2020 | $255,000 | +4.9% | 7,620 | -28.1% | 0.00% | – |
| Q1 2020 | $243,000 | – | 10,603 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 17,161,713 | $1,062,825,000 | 82.06% |
| RTW INVESTMENTS, LP | 3,544,248 | $219,495,000 | 3.68% |
| Cormorant Asset Management, LP | 1,437,807 | $89,043,000 | 2.12% |
| Redmile Group, LLC | 2,686,234 | $166,358,000 | 2.01% |
| ACUTA CAPITAL PARTNERS, LLC | 92,500 | $5,729,000 | 1.56% |
| Pinz Capital Management, LP | 34,200 | $2,118,000 | 0.96% |
| Birchview Capital, LP | 20,000 | $1,239,000 | 0.71% |
| HighVista Strategies LLC | 17,668 | $1,094,000 | 0.70% |
| GILDER GAGNON HOWE & CO LLC | 1,470,841 | $91,089,000 | 0.45% |
| Perceptive Advisors | 671,978 | $41,616,000 | 0.45% |